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Objective: Despite signiﬁcant improvement in survival of gastrointestinal stromal tumors (GIST) due to
use of tyrosine kinase inhibitors, surgery still represents the important part of clinical management. The
aim of our study was to retrospectively analyze prognosis of GIST depending on the success of surgical
treatments and utilization of chemotherapy in transitional country with relatively limited resources.
Methods: cohort of consecutive patients operated for GIST in tertiary medical center, within time frame
1999e2012. Results: 54 patients, in age range 20e85 years (63.3 ± 14.7), male to female ratio 28
(51.9%):26 (48.1%), respectively. Complete excision with clean resection margins (R0) was obtained in 44
(81.5%)of total patients i.e. 44/47 (93.6%) of localized GISTs. Mean follow up was 3.9 ± 3.3 years and 19
patients (35.2%) received imatinib. Rate of overall survival was 40 (74.1%), disease-free survival 31 (57.4%)
and 20 (37.0%) experienced recidivism. Follow-up parameters showed signiﬁcant difference in connec-
tion with utilization of imatinib, completeness of resection and existence of metastatic disease (all
p < 0.05). ROC analyzes revealed critical value of Ki-67 > 9% as signiﬁcant predictor of long-term mor-
tality; sensitivity 64.3% [95%CI ¼ 35.1e87.2]; speciﬁcity 75.0% [58.8e87.3]; (AUC ¼ 0.693; p ¼ 0.049).
Conclusion: Rate of complete resections in studied sample of patients from transitional background was
overall peer comparable with reports from the developed countries. On the other hand, relatively
dominant prognostic position of surgical treatments might be consequence of limited utilization of
adjuvant treatment with tyrosine kinase inhibitors.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.tumor; TNM, classiﬁcation of
ases); Ki-67, “Kiel 67” prolif-
ic tumor margins.
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Gastrointestinal stromal tumors (GIST) are rare cancerous dis-
eases with incidence of around 10 cases per million [1]. GIST makes
1e3% of total cancer burden in gastrointestinal tract, however, at
the same time it is the most common gastrointestinal mesen-
chymal tumor [2,3]. Important changes in natural course and
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proto-oncogene [4]. C-kit encrypts type III receptor of tyrosine ki-
nase, which mediates regulation of cell cycle and differentiation. In
case of GIST, gain of function mutation causes that c-kit becomes
constitutively activated, without binding of ligand and necessity of
dimerization [4]. Important role of c-kit in pathophysiology of
neoplastic growth ﬁnally led to clinical use of exceedingly efﬁcient
chemotherapy with tyrosine kinase inhibitors [5]. Due to a con-
cealed malignant potential and lacking of connection with tradi-
tional TNM-staging several speciﬁc prognostic systems were
developed. The most notable parameters of GIST's malignant
behavior occur in dependence with size of tumor, number of mi-
toses, localization within gastrointestinal tract and existence of
metastases [6e8]. In addition, nuclear protein Ki-67 that is
expressed during the course of cancerous growth offers relatively
solid representation of the link existing between mitoses and tu-
mor dimensions [9]. Ki-67 was actually found to be in correlation
with prognosis of GIST and for that reason is being frequently
applied as supplementary diagnostic tool [10].
Combination of surgical treatments and use of tyrosine kinase
inhibitors became resourceful and efﬁcient armamentarium for
treatment of GIST, depending on clinical stage and extent of disease
[11,12]. Although the role and position of surgical treatment has
been evaluated in the most developed Western countries, only
limited number of studies offered thorough prognostic analyzes in
concern to economically, organizationally and technically less
developed health systems. In those circumstances one could
reasonably expect that limited health budgets experience the non-
negligible challenges for rehearsing optimal level of cancer
screening, early detection, having sufﬁcient availability and com-
petences of surgical treatments, along with presumable underuti-
lization of chemotherapy. The aim of our study was to analyze
temporal effects of surgery and targeted chemotherapy in tertiary
medical center from transitional country. Assessment of surgical
treatment and utilization of tyrosine kinase inhibitors was studied
in connection with known prognostic parameters in cohort of pa-
tients with long-term postoperative follow up.Table 1
Characteristics of patients, GISTs and treatments.
n (%) or mean ± SD
Age (years) 63.3 ± 14.7
Gender Male 28 (51.9%)
Female 26 (48.1%)
Localization Stomach 29 (53.7%)
Small intestine 17 (31.5%)
Colon and rectum 5 (9.3%)
Extraintestinal
and peritoneal
3 (5.6%)
Maximal
dimension (mm)
63.9 ± 52.5
Ki67 (%) 0.09 ± 0.07
Patohistologic grade Low grade 24 (45.3%)
Intermediate grade 12 (22.6%)
High grade 17 (32.1%)
Metastatic disease 10 (18.5%)
Cell type Spindle 32 (59.3%)
Mixed (including epitheloid) 22 (40.7%)2. Patients and methods
Study was performed in tertiary medical center and it included
retrospective analyzes on consecutive sample of patients treated
surgically for gastrointestinal stromal tumor in single center, dur-
ing the time frame 1.1.1999e31.12.2012. The diagnosis of GIST was
established by patohistology and immunohistochemistry using c-
kit, Ki-67, SMA, S-100 [13,14]. Tumors were classiﬁed as low, in-
termediate and high grade according to dimension, number of
mitoses and localization [15].
Analyzes of surgical treatments included type of operation
(elective vs. urgent surgery); completeness of resection (gross total
resection veriﬁed by patohistology, incomplete resection, and
palliative tumor reduction); and early postoperative complications
(wound dehiscence, infection, hemorrhage, renal failure, mortal-
ity). Data on oncological treatment and late postsurgical follow up
were not available for 8 patients (14.8%).Level of resection Gross total resection 44 (81.5%)
Incomplete resection 6 (11.1%)
Tumor reduction 4 (7.4%)
Type of surgery Elective 42 (77.8%)
Urgent 12 (22.2%)
Early postoperative complications 6 (11.1%)
Using Imatinib 19 (35.2%)
Mortality during follow up 12 (22.2%)
Data labels: n e number of patients; SD e standard deviations; Ki-67 e “Kiel 67”
proliferative index.3. Ethical issues
Study was approved by the ethical committee of University
Hospital Center “Sestre Milosrdnice” in line with the good clinical
practice guidelines. Patients were included upon signing of written
informed consent by patient themselves or by legal representative
i.e. family member in case patient's has deceased.4. Statistical analyses
Population and studied groups were analyzed with descriptive
statistic and presented as a percentage or means combined with
standard deviations. Characteristics of treatments and GISTs were
tested for differences with Chi square tests. Numeric data were
tested for differences using ManneWhitney U test or Kruskal
Wallis. Correlation of studied parameters with clinical outcomes
was done by Spearman Rho. Impact of Ki-67 on mortality was
calculated with ROC analyzes. Analyzes of survival was performed
using KaplaneMeier estimator. P value less than 0.05 was consid-
ered signiﬁcant. Statistical analyses were done by experienced
statistician using Statistica v.10 forWindows (StatSoft inc. USA) and
MedCalc for Windows v. 12.2 (MedCalc Software, Belgium).
5. Results
Study population included 54 consecutive patients operated for
GIST, in time frame 1999e2012. Forty one (75.9%) of patients were
operated in the period 2005e2012. Mean age of patient was
63.3 ± 14.7 years (range 20e85). There was a slight predominance
of male patients over female; 28 (51.9%):26 (48.1%), respectively.
The commonest tumor localization of GIST was in stomach, fol-
lowed by small intestine, colon and extraintestinal/peritoneal. All
cases were seropositive for c-kit. Characteristics of studied popu-
lation are shown in Table 1.
Mean follow up lasted for 3.9 ± 3.3 years, in range 1e13.5.
Nineteen patients (35.2%) received imatinib chemotherapy, due to
advanced clinical grade of tumor or recurrence of GIST. Metastatic
disease was found in 10 (18.5%) of studied patients. Rate of overall
survival was 40 (74.1%), disease-free survival 31 (57.4%) and 20
(37.0%) had recidivism of GIST during the study course. Follow-up
parameters showed signiﬁcant difference in connection with uti-
lization of imatinib, completeness of resection and existence of
metastatic disease (all p < 0.05), Table 2.
There was 42 (77.8%) of elective procedures vs. 12 (22.2%) of
urgent surgeries. Urgent procedures were performed due to acute
abdominal pain (n ¼ 8), intractable gastrointestinal bleeding
Table 2
Analyzes of prognostic parameters.
Type of surgery Chi square Complete resection Chi square Metastatic disease Chi square Imatinib n ¼ 19 Chi square
Elective Urgent Yes No No Yes Yes No
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
GIST recidive 13 (31.0%) 7 (58.3%) 0.083 12 (27.3%) 8 (80.0%) 0.002 13 (29.5%) 7 (70.0%) 0.017 8 (22.9%) 12 (63.2%) 0.003
Disease-free survival 26 (61.9%) 5 (41.7%) 0.211 29 (65.9%) 2 (20.0%) 0.008 29 (65.9%) 2 (20.0%) 0.008 25 (71.4%) 6 (31.6%) 0.005
Overall survival 34 (81.0%) 7 (58.3%) 0.106 36 (81.8%) 5 (50.0%) 0.034 36 (81.8%) 5 (50.0%) 0.034 30 (85.7%) 11 (57.9%) 0.022
Data labels: Imatinib e patients using chemotherapy during study course; Statistical signiﬁcance presented in bold text.
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ferences or correlations were observed between groups of surgery
electiveness and studied clinical parameters (all p > 0.05).
KaplaneMeier analyzes of survival was also not signiﬁcant on this
grounds (p ¼ 0.985).
Complete excision with clean resection margins (R0) was ob-
tained in 44 (81.5%) of patients (i.e. 44/47 for the subgroup of
localized GISTs), whilst incomplete resection was found in 6/54
(11.1%) and remainder of 4/54 (7.4%) had palliative tumor reduction.
Signiﬁcant correlations were found between completeness of
resectionwith tumor localizations (Rho¼ 0.286; p¼ 0.036); grades
of risk (Rho ¼ 0.335; p ¼ 0.014); prevalence of metastatic disease
(Rho ¼ 0.633; p < 0.001); electiveness of surgery (Rho ¼ 0.317;
p ¼ 0.020) and Ki-67 (Rho ¼ 0.273; p ¼ 0.046). Level of resection
was correspondingly signiﬁcant in KaplaneMeier analyzes of sur-
vival (p ¼ 0.034), Fig. 1.
Six (11.1%) procedures were burdened with early postoperative
complications, as follows: 2 wound dehiscence with local infection,
2 postoperative hemorrhages, and there were included 2 cases of
acute renal failure. One of operations was performed in hypo-
volemic shock due to incontrollable gastric hemorrhage. ThisFig. 1. KaplaneMeier analyzes of survival in connection with completeness of surgical
resection. KaplaneMeier analyzes of survival for studied surgical resections; complete
excision with patohistologic veriﬁcation, incomplete resection (R1) resection-unclear
resection tumor margins, and tumor reduction-unresectable tumors. Table shows
time dynamics for number of cases per studied group. Model was statistically signif-
icant (p ¼ 0.034).female patient was of advanced age, and deceased on the 3rd
postoperative day due to multiorgan failure syndrome.
There was no signiﬁcance of tumor localizations, considering
differences in prevalence or correlation with mortality (p ¼ 0.343),
(Rho ¼ 0.012; p ¼ 0.931). Localizations of tumors correlated posi-
tively with age of patients (Rho ¼ 0.359; p ¼ 0.008); although the
mean age at operation was not signiﬁcant considering the tumor
sitewith 58.3 ± 16.2 years vs. 68.3 ± 11.2 vs. 72.0 ± 7.5 vs. 67.7 ± 11.9
(p ¼ 0.062) for stomach vs. small intestine vs. colon and rectum vs.
extraintestinal GISTs, respectively. There was no connection of
gender with any of studied characteristics of patients, tumors, pa-
rameters of surgical treatment or prognosis (all p > 0.05).
Spindle cell type was more common with 32 (59.3%), than
mixed type (including 2 cases of epitheloid) 22 (40.7%). No statis-
tically signiﬁcant relationships were found for cellular type with
studied clinical or prognostic parameters (all p > 0.05).
Mean diameter of GISTwas 63.9 ± 52.5mm,medianwas 50mm,
in range 4e250 mm. Diameter positively correlated with patohis-
tologic grade of risk (Rho ¼ 0.801; p < 0.001). There was no dif-
ference or correlation of tumor dimensions with localizations (both
p > 0.05). Mean expression of Ki-67 was 0.09 ± 0.07%, with range
0.01e0.30%. Ki-67 revealed signiﬁcant correlations with prognostic
parameters; grade of risk (Rho ¼ 0.733; p < 0.001), maximal
dimension of tumor (Rho ¼ 0.511; p < 0.001), prevalence of met-
astatic disease (Rho ¼ 0.318; p ¼ 0.019), completeness of surgical
excision (Rho ¼ 0.273; p ¼ 0.046), mortality (Rho ¼ 0.294;
p ¼ 0.031). There was no signiﬁcant correlation of Ki-67 with
localization of GIST and cellular type (p > 0.05). Mean Ki-67 score
was of signiﬁcantly different expression patterns in immunohis-
tochemistry depending on the patohistologic grade of tumor
0.04 ± 0.03% vs. 0.07 ± 0.03% vs. 0.15 ± 0.07% for low, inter-
mediary and high grade of GIST, respectively (p < 0.001). Existence
of metastatic disease was also of statistically signiﬁcant difference
in terms of Ki-67; 0.07 ± 0.05% for non-metastatic vs. 0.15 ± 0.10
for metastatic disease (p ¼ 0.022). Patients that have died in the
course of study follow up, similarly displayed increased Ki-67
values; 0.13 ± 0.08 vs. 0.07 ± 0.06, (p ¼ 0.034). ROC analyzes
revealed critical value of Ki-67 > 9% being signiﬁcant cutoff point as
landmark of long-term mortality; with sensitivity of 64.3% [95%
CI ¼ 35.1e87.2], speciﬁcity of 75.0% [58.8e87.3], positive likelihood
ratio 2.6 [1.7e4.0] and negative likelihood ratio of 0.48 [0.2e1.2];
(AUC ¼ 0.693; p ¼ 0.049).6. Discussion
Croatia faces challenges of inadequate and repetitively
decreasing national healthcare budgets, which are for several times
lower considering per capita spending on healthcare in comparison
with themost developed industrialized countries. Later might be of
particular interest in the ﬁeld of GISTs due to organizational issues;
lower availability of diagnostics, relatively modest number of ac-
tivities aiming at early detection of cancer or optimal surgical
management considering the level of technical and personnel
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ability and coverage of chemotherapy with tyrosine kinase in-
hibitors [16,17]. This study systematically analyzed treatments of
GIST, particularly the temporal effects of surgical treatments and
utilization of chemotherapy in connection with prognostic
parameters.
GISTs were most commonly found in stomach and small intes-
tine, correspondingly to earlier reports [18]. Interestingly, in our
series, tumor localization showed positive correlation with age of
patients, making more aboral tumors being diagnosed at older age
of patient [18]. Later is more in favor of symptomatology driven
diagnostics and/or treatment, rather than primer predilection of
particular age for speciﬁc localization of tumor.
Nearly one third of GISTs was of high grade, whilst metastatic
disease happened in nearly one ﬁfth of patients, where both are
being in line with earlier reports [19]. Grade of patohistologic risk
was in positive correlation with existence of metastatic disease,
completeness of surgical resection and long term mortality [20].
Median diameter of tumors was 50 mm (range 4e250), which is
also congruent with most of the studies [19]. GIST dimensions
showed positive correlations with patohistologic grade and Ki-67.
Interestingly, dimensions showed positive correlation with exis-
tence of metastatic disease, however no signiﬁcant difference was
found between dimensions of primer tumor in metastatic disease
versus ones without metastases. Diameter of GIST failed to display
connections with studied characteristics of surgical treatment as;
level of resection, electiveness of surgery, rate of short term
complication and long term prognosis.
Ki-67 showed positive correlations with occurrence of meta-
static disease and completeness of surgical resection. Although
tumors with complete resection had lower median Ki-67 values in
comparisonwith incomplete resections or palliative reductions, the
difference itself was not statistically signiﬁcant. Critical cutoff of Ki-
67 being greater than 9% showed statistically signiﬁcant association
with overall survival in studied set of patients. This critical point
might be used as additional landmark of high risk grade GIST,
although further studies and additional standardizations would be
required. Cellular types of tumor did not have any meaningful in-
ﬂuence on clinical course and prognosis, as earlier reported [13,21].
Greater proportion of studied surgical treatments was per-
formed as elective procedures. Although there was signiﬁcant dif-
ference on basis of electiveness for grade of tumor, localizations and
existence of metastatic disease, there was no signiﬁcant difference
in terms of overall survival. Rate and individualities of early post-
operative complications had no signiﬁcant effect on the long
prognosis in studied set of patients.
Success rate of excisions was satisfactory for localized tumors,
whilst overall rate was in close connection with prevalence of
advanced and metastatic forms of disease, as previously reported
[1,18,22e28]. Complete surgical resection with clear resection
margins veriﬁed by patohistology was attained in 81.5% of patients
(i.e. 94% of only localized GISTs), incomplete resection (R1 resec-
tion) in 11.1%, and remainder of 7.4% were palliative tumor re-
ductions. Latter happened in patients with
extraintestinaleperitoneal localizations, presence of metastatic
disease, or as in single case, in which tumor consumed great
abdominal vessels [28]. Signiﬁcant correlations were found be-
tween completeness of resection with tumor localizations, grade of
risk, existence of metastatic disease, electiveness of surgery and Ki-
67. Attainability of resection showed statistically signiﬁcant inﬂu-
ence on the overall survival, which was also conﬁrmed in
KaplaneMeier analyzes. Sicklick et al. recently reported on com-
parable prognostic outcomes between complete and incomplete
(R1) resections, which is in contrast to statistically signiﬁcant
prognostic difference of resections found in our study [29]. Latercould be explained through relatively lower utilization of tyrosine
kinase inhibitors in compare to former study [29]. Although one
must also not disregard the important confounders of dissimilar
settings and time-frames. This noticeable difference in survival
might be improved, even in industrially less developed countries by
increasing the availability of therapywith tyrosine kinase inhibitors
as imatinib, especially for the adjuvant settings [12,16]. Dominant
part of imatinib utilization in our study was reserved for advanced
disease or recurrences, whilst only negligible number of cases
received adjuvant chemotherapy. Watchful waiting follow up of
intermediary or high grade non-metastatic disease after complete
excisionwas far the most common pattern of imatinib utilization in
our settings; however it seems likely that similar practice also
commonly exists in circumstances of limited health budgets
worldwide. One must note that introducing of the tyrosine kinase
inhibitors in early course of GIST treatment might offer auxiliary
improvements to the outcomes of surgery [30]. Later also un-
derscores the value added by applying of multidisciplinary team
approach in treatment of GISTs.
In conclusion, GIST is regarded as neoplastic disease with con-
cealed malignant potential. Overall success rates of surgical treat-
ments in studied set of patients with localized disease were peer
comparable with the reports from most developed industrialized
nations. We have also noticed a relatively dominant position of
surgical treatment for prognosis of GIST, especially in settings of
limited availability of tyrosine kinase inhibitors for adjuvant set-
tings. Lattermight be explained by time-holdups inwidening of the
drug coverage indications, as well as challenges of limited ﬁnancial
resources that commonly exist in transitional countries.Ethical approval
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